Identification of Breast Cancer Inhibitors Specific for G Protein-Coupled Estrogen Receptor (GPER)-Expressing Cells
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim..
Together with estrogen receptors ERα and ERβ, the G protein-coupled estrogen receptor (GPER) mediates important pathophysiological signaling pathways induced by estrogens and is currently regarded as a promising target for ER-negative (ER-) and triple-negative (TN) breast cancer. Only a few selective GPER modulators have been reported to date, and their use in cancer cell lines has often led to contradictory results. Herein we report the application of virtual screening and cell-based studies for the identification of new chemical scaffolds with a specific antiproliferative effect against GPER-expressing breast cancer cell lines. Out of the four different scaffolds identified, 8-chloro-4-(4-chlorophenyl)pyrrolo[1,2-a]quinoxaline 14 c was found to be the most promising compound able to induce: 1) antiproliferative activity in GPER-expressing cell lines (MCF7 and SKBR3), similarly to G15; 2) no effect on cells that do not express GPER (HEK293); 3) a decrease in cyclin D1 expression; and 4) a sustained induction of cell-cycle negative regulators p53 and p21.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
ChemMedChem - 12(2017), 16 vom: 22. Aug., Seite 1279-1285 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aiello, Francesca [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.10.2017 Date Revised 21.04.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cmdc.201700145 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM272029831 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM272029831 | ||
| 003 | DE-627 | ||
| 005 | 20231224234006.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cmdc.201700145 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0906.xml |
| 035 | |a (DE-627)NLM272029831 | ||
| 035 | |a (NLM)28520140 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aiello, Francesca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Identification of Breast Cancer Inhibitors Specific for G Protein-Coupled Estrogen Receptor (GPER)-Expressing Cells |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.10.2017 | ||
| 500 | |a Date Revised 21.04.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. | ||
| 520 | |a Together with estrogen receptors ERα and ERβ, the G protein-coupled estrogen receptor (GPER) mediates important pathophysiological signaling pathways induced by estrogens and is currently regarded as a promising target for ER-negative (ER-) and triple-negative (TN) breast cancer. Only a few selective GPER modulators have been reported to date, and their use in cancer cell lines has often led to contradictory results. Herein we report the application of virtual screening and cell-based studies for the identification of new chemical scaffolds with a specific antiproliferative effect against GPER-expressing breast cancer cell lines. Out of the four different scaffolds identified, 8-chloro-4-(4-chlorophenyl)pyrrolo[1,2-a]quinoxaline 14 c was found to be the most promising compound able to induce: 1) antiproliferative activity in GPER-expressing cell lines (MCF7 and SKBR3), similarly to G15; 2) no effect on cells that do not express GPER (HEK293); 3) a decrease in cyclin D1 expression; and 4) a sustained induction of cell-cycle negative regulators p53 and p21 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 5-dihydropyrrolo[1,2-a]quinoxaline | |
| 650 | 4 | |a GPER | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a estrogen | |
| 650 | 4 | |a pyrrolo[1,2-a]quinoxaline | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Cyclin-Dependent Kinase Inhibitor p21 |2 NLM | |
| 650 | 7 | |a Estrogen Receptor alpha |2 NLM | |
| 650 | 7 | |a Estrogen Receptor beta |2 NLM | |
| 650 | 7 | |a Quinoxalines |2 NLM | |
| 650 | 7 | |a Receptors, G-Protein-Coupled |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
| 650 | 7 | |a Cyclin D1 |2 NLM | |
| 650 | 7 | |a 136601-57-5 |2 NLM | |
| 700 | 1 | |a Carullo, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Giordano, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Spina, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Nigro, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Garofalo, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Tassini, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Costantino, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Vincetti, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Bruno, Agostino |e verfasserin |4 aut | |
| 700 | 1 | |a Radi, Marco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ChemMedChem |d 2006 |g 12(2017), 16 vom: 22. Aug., Seite 1279-1285 |w (DE-627)NLM164619577 |x 1860-7187 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2017 |g number:16 |g day:22 |g month:08 |g pages:1279-1285 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cmdc.201700145 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2017 |e 16 |b 22 |c 08 |h 1279-1285 | ||